BIOHIT

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk

BIOHIT Healthcare Articles

• Point-of-care testing for atrophic gastritis can help relieve the pressure on endoscopy services

Patients with atrophic gastritis due to Helicobacter pylori (H. pylori) infection or autoimmune disease are known to have an increased risk of gastric adenocarcinoma, the 16th most common cancer in the UK and a frequent cause of death globally. British Society of Gastroenterology (BSG) guidelines state that non-invasive identification of high-risk patients prior to endoscopy is key for the early detection and diagnosis of cancer, and to improve cancer survival rates. Point-of-care testing (POCT) for atrophic gastritis with the GastroPanel® Quick Test NT is an effective triage tool that can be used both within and outside of secondary care settings, aligning with the current UK government’s drive to move healthcare away from hospitals and towards community and primary care environments.

• Closing the quality gap with Helicobacter pylori Control+ for rapid urease tests

Rapid urease tests – such as the ULTRA-FAST UFT300 H. pylori Quick Test from BIOHIT HealthCare – are helping to quickly determine H. pylori infection during endoscopy procedures. However, these tests often operate outside the oversight of point-of-care testing (POCT) teams responsible for maintaining testing standards. In this blog, we explore the importance of bridging the gap between endoscopy and POCT teams, the role of internal quality controls in ensuring reliable results, and how H. pylori Control+ can enhance diagnostic confidence.

• The future of point-of-care testing in the healthcare landscape

People living with long-term health conditions, such as inflammatory bowel disease, require regular monitoring and medical support to manage their symptoms and maintain their quality of life, but challenges such as illness or remote location often limit access to in-person care. In this blog, Tony Cambridge, Managing Director of Thornhill Healthcare Events and Consultancy and former Lead Biomedical Scientist at University Hospitals Plymouth NHS Trust, England, discusses how the ongoing shift towards point-of-care testing with innovative user-friendly devices supports decentralised disease monitoring and personalised care.

• Elevating gastrointestinal diagnostics with the ULTRA-FAST UFT300 Helicobacter pylori Quick Test

The bacterium Helicobacter pylori (H. pylori) is a common cause of several gastrointestinal disorders, including dyspepsia, peptic ulcers and atrophic gastritis. The rapid diagnosis of H. pylori infection is therefore key to timely treatment and can help to prevent the development of digestive diseases. In this blog Paula Pendry, Endoscopy Sister at Northern Care Alliance NHS Foundation Trust, explains how performing a highly sensitive, specific urease test during routine gastroscopy procedures can be crucial for streamlining the diagnostic and treatment pathways for H. pylori.

• The inside edge on Peptest for the diagnosis of silent reflux

Andrew Woodcock, Chief Scientific Officer at RD Biomed Limited discusses the advantages of using Peptest to help diagnose silent reflux. Silent reflux is caused by gastric contents travelling up the oesophagus and into the throat or nasal cavity. This results in a range of non-specific symptoms often misinterpreted as problems of the throat, such as frequent throat clearing, difficulty swallowing, the feeling of a lump or globus in the throat, and a hoarse, tight or croaky voice. If untreated, prolonged exposure of tissues to stomach pepsin can cause further chronic complications, such as esophagitis, ulcers and even cancer.

• Tackling the challenge of Helicobacter pylori in record time with the ULTRA-FAST UFT300 Quick Test

Helicobacter pylori infection is a common – yet potentially curable – cause of a number of gastrointestinal disorders, including dyspepsia, peptic ulcer disease, and precancerous conditions such as atrophic gastritis (AG). Fast and efficient diagnosis of H. pylori infection with a rapid urease test (RUT) during gastroscopy can therefore go a long way to help diagnose these conditions. In this blog, Win Ho, Area Sales Manager at BIOHIT HealthCare, explores how the H. pylori ULTRA-FAST UFT300 Quick Test from BIOHIT HealthCare plays a pivotal role in the diagnostic pathway, providing high sensitivity and specificity in record time.

BIOHIT Healthcare Case Studies

• STREAMLINING HELICOBACTER PYLORI DIAGNOSIS WITH ULTRA-FAST UREASE TESTING CASE STUDY FROM AN NHS TRUST ENDOSCOPY NETWORK

Helicobacter pylori (H. pylori) is a Gram-negative bacterium that colonises the stomach of approximately half of the world’s population, and approximately 30 per cent of individuals in the UK. Although the majority of infected individuals are asymptomatic, many will develop inflammation and disruption to the protective mucus layer of the stomach. This increases the risk of gastrointestinal bleeding and also leaves sufferers more susceptible to a range of severe and potentially life-threatening digestive disorders.

• USING PEPTEST® FOR THE RAPID, NON-INVASIVE DIAGNOSIS OF LARYNGOPHARYNGEAL REFLUX

Peptest is a non-invasive diagnostic tool for reflux that uses a double monoclonal antibody capture technique incorporated into an easy-to-use lateral flow device. The test can detect the presence of pepsin in samples from the upper digestive and respiratory tracts, providing a fast, reliable and accurate measure of the severity of reflux, and aiding timely treatment. Jane Shaw is a consultant speech and language therapist (SLT) based at Doncaster Royal Infirmary, one of the four hospitals that make up the Doncaster and Bassetlaw Teaching Hospitals NHS Trust.She has been using Peptest in routine clinical practice for several years to help identify whether LPR is the underlying cause of a patient’s vocal problems

• PEPTEST Case study from a Consultant ENT Surgeon

Peptest is the first non-invasive test that diagnoses reflux related conditions. It is an innovative test that quickly and easily identifies patients who reflux gastric juice and therefore pepsin that is found in the stomach. Gastric reflux is a common condition that everyone experiences in small amounts, however, in excess gastric reflux can contribute to a wide range of conditions. Mr Mark Watson, a consultant ENT surgeon at Doncaster Royal Infirmary, uses Peptest to test for laryngopharyngeal reflux, a disease that differs from standard indigestion and heartburn and is commonly known as ‘silent reflux’.

• PEPTEST Case study from a consultant ENT head and neck surgeon

Mr Taran Tatla, a consultant ENT head and neck surgeon at Northwick Park and St Mark’s Hospital, London, has a special interest in laryngopharyngeal reflux (LPR) and uses Peptest early to help diagnose the condition in cancer patients undergoing rehabilitation after surgery or therapy, such as chemoradiation. He is also conducting research and is involved in trials looking at the significance of reflux as an under-recognised underlying risk factor for the development of certain tumours, as well as the potential role of Peptest for better triaging of patients in primary care who present with worrying (but non specific) throat symptoms.

BIOHIT White Papers

• A pitch-perfect approach to diagnosing laryngopharyngeal reflux – This white paper explores mechanisms of voice production, current approaches to diagnosing and treating voice disorders, and the benefits of a novel diagnostic tool that is enhancing the management of LPR in several UK NHS trusts.
• The Core Microbiota in a Healthy Population – This white paper explores the composition and function of the gut microbiome, its effects on a systemic level, and how advances in microbial profiling are enhancing our understanding of health and disease.

Discover More

BIOHIT Video & Webinars

• Explore a range of free to access webinars and videos from BIOHIT HealthCare

Discover More

BIOHIT

• Explore BIOHIT HealthCare brochures and publications

Learn More